MedTrace Logo

Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

NCT01361568 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 203

Last updated 2014-05-29

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.

Conditions

  • Postoperative Pain

Interventions

DRUG

CR845

Single i.v. dose (0.04 mg/kg) administered preoperatively

DRUG

Placebo

Single i.v. dose administered preoperatively

DRUG

CR845

Single i.v. dose (0.04 mg/kg) administered postoperatively for pain

DRUG

Placebo

Single i.v. dose administered postoperatively for pain

Sponsors & Collaborators

  • Cara Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Tong-Joo Gan, MD, MHS · Duke University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-04-30
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01361568 on ClinicalTrials.gov